On October 5, 2026, Azenta's Board approved a restructuring plan within its Multiomics segment to consolidate North American laboratory sites and simplify organizational structure. The company estimates aggregate pre-tax charges of approximately $11.0 million to $13.0 million, including roughly $9.0 million in asset impairment and $3.0 million in severance costs. Future cash expenditures are estimated at $7.0 million. Azenta expects to recognize substantially all charges during fiscal 2027 and complete the plan by March 31, 2027, targeting annualized cost savings of approximately $11.0 million. This initiative is separate from earlier restructuring actions completed in August and September 2026 that did not result in material charges. Azenta operates in the life sciences industry, providing sample management solutions and multiomics services.
